KBC Group NV boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 19.7% during the first quarter, Holdings Channel reports. The institutional investor owned 11,914 shares of the specialty pharmaceutical company’s stock after buying an additional 1,961 shares during the period. KBC Group NV’s holdings in ANI Pharmaceuticals were worth $590,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Thrivent Financial for Lutherans boosted its stake in shares of ANI Pharmaceuticals by 5.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,300 shares of the specialty pharmaceutical company’s stock valued at $261,000 after buying an additional 240 shares during the last quarter. CAPROCK Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 6.7% in the first quarter. CAPROCK Group Inc. now owns 4,591 shares of the specialty pharmaceutical company’s stock valued at $227,000 after buying an additional 287 shares during the last quarter. Comerica Bank boosted its stake in shares of ANI Pharmaceuticals by 3.8% in the first quarter. Comerica Bank now owns 8,855 shares of the specialty pharmaceutical company’s stock valued at $486,000 after buying an additional 323 shares during the last quarter. US Bancorp DE boosted its stake in shares of ANI Pharmaceuticals by 4.9% in the first quarter. US Bancorp DE now owns 8,592 shares of the specialty pharmaceutical company’s stock valued at $426,000 after buying an additional 405 shares during the last quarter. Finally, Chicago Equity Partners LLC boosted its stake in shares of ANI Pharmaceuticals by 5.2% in the first quarter. Chicago Equity Partners LLC now owns 17,360 shares of the specialty pharmaceutical company’s stock valued at $859,000 after buying an additional 860 shares during the last quarter. Institutional investors own 55.52% of the company’s stock.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ ANIP) opened at 45.99 on Tuesday. ANI Pharmaceuticals, Inc. has a 1-year low of $42.56 and a 1-year high of $70.92. The company has a market cap of $535.19 million, a PE ratio of 143.72 and a beta of 2.95. The stock’s 50 day moving average price is $47.10 and its 200-day moving average price is $53.72.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, May 4th. The specialty pharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.04. The business had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $39.63 million. ANI Pharmaceuticals had a net margin of 2.58% and a return on equity of 23.76%. The company’s revenue for the quarter was up 77.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.76 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “KBC Group NV Buys 1,961 Shares of ANI Pharmaceuticals, Inc. (ANIP)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/06/20/kbc-group-nv-buys-1961-shares-of-ani-pharmaceuticals-inc-anip.html.

Several equities research analysts have weighed in on the company. Roth Capital set a $56.00 price objective on ANI Pharmaceuticals and gave the stock a “hold” rating in a research note on Saturday, May 6th. Guggenheim reissued a “buy” rating and set a $80.00 price objective on shares of ANI Pharmaceuticals in a research note on Thursday, April 6th. ValuEngine cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, TheStreet cut ANI Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Monday, April 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $67.83.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.